A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex in a Range of Oral pH Environments in Healthy Subjects

Trial Profile

A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex in a Range of Oral pH Environments in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Bladder dysfunction; Cancer pain; Glioblastoma; Muscle spasticity; Neuropathic pain; Stomatitis
  • Focus Pharmacokinetics
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2016 Status changed from not yet recruiting to discontinued.
    • 13 Aug 2015 Planned End Date changed from 1 Nov 2015 to 1 May 2016, as reported by ClinicalTrials.gov.
    • 13 Aug 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top